FENC Key Statistics, Chart & Performance
The current stock price of FENC is 8.19 USD. In the past month the price decreased by -1.68%. In the past year, price increased by 35.15%.
FENC Latest News, Press Relases and Analysis
FENC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.25B | ||
| AMGN | AMGEN INC | 15.8 | 185.98B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 111.17B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.15B | ||
| INSM | INSMED INC | N/A | 43.92B | ||
| NTRA | NATERA INC | N/A | 32.78B | ||
| BIIB | BIOGEN INC | 10.88 | 26.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 21.98B | ||
| INCY | INCYTE CORP | 16.27 | 20.40B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About FENC
Company Profile
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Company Info
FENNEC PHARMACEUTICALS INC
PO Box 13628, 68 Tw Alexander Dr
RESEARCH TRIANGLE PARK NORTH CAROLINA 27709 US
CEO: Rostislav Raykov
Employees: 36
Phone: 19196364530
FENNEC PHARMACEUTICALS INC / FENC FAQ
What does FENNEC PHARMACEUTICALS INC do?
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
What is the current price of FENC stock?
The current stock price of FENC is 8.19 USD. The price increased by 3.8% in the last trading session.
Does FENNEC PHARMACEUTICALS INC pay dividends?
FENC does not pay a dividend.
What is the ChartMill rating of FENNEC PHARMACEUTICALS INC stock?
FENC has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of FENC stock?
FENNEC PHARMACEUTICALS INC (FENC) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for FENC stock?
FENNEC PHARMACEUTICALS INC (FENC) currently has 36 employees.
Can you provide the market cap for FENNEC PHARMACEUTICALS INC?
FENNEC PHARMACEUTICALS INC (FENC) has a market capitalization of 227.93M USD. This makes FENC a Micro Cap stock.
FENC Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to FENC. When comparing the yearly performance of all stocks, FENC is one of the better performing stocks in the market, outperforming 79.22% of all stocks.
FENC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to FENC. Both the profitability and financial health of FENC have multiple concerns.
FENC Financial Highlights
Over the last trailing twelve months FENC reported a non-GAAP Earnings per Share(EPS) of -0.23. The EPS decreased by -475% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.09% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
FENC Forecast & Estimates
11 analysts have analysed FENC and the average price target is 13.77 USD. This implies a price increase of 68.13% is expected in the next year compared to the current price of 8.19.
For the next year, analysts expect an EPS growth of -132665236383229020% and a revenue growth -21.01% for FENC